Xcyte Therapies Inc.
This article was originally published in Start Up
Executive Summary
Xcyte Therapies, a company 're-started' through the 1997 merger of CDR Therapeutics and CellGenEx, is developing ex vivo cellular therapies for immune system stimulation using monoclonal antibodies conjugated to magnetic beads.